Levosert One

Levonorgestrel, the active ingredient in Levosert One, is a progestin presented as a 52 mg intrauterine system for intrauterine use. It prevents pregnancy in women of reproductive age. GNH USA supplies Levosert One as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levonorgestrel, a progestin hormonal contraceptive, is used to prevent pregnancy. - Contraception: provides up to three years of reliable pregnancy prevention when placed correctly in the uterus.

Levosert One may cause a range of adverse reactions, most of which are mild and related to the device or hormone release.

Common Side Effects: - Irregular vaginal bleeding or spotting: changes in bleeding pattern are frequent during the first months. - Amenorrhea: absence of periods may occur after continued use. - Pelvic or abdominal pain: discomfort around the insertion site is common. - Device expulsion: the IUS may be partially or fully expelled. - Insertion site irritation: local soreness or swelling after placement. - Hormonal effects: acne, breast tenderness, or mood changes.

Serious or Rare Side Effects: - Uterine perforation: a rare event during insertion that can cause abdominal injury. - Pelvic infection: severe infection requiring medical treatment. - Ectopic pregnancy: occurs if pregnancy happens despite the device. - Severe allergic reaction: anaphylaxis or hypersensitivity to levonorgestrel or device materials. - Device migration: movement of the IUS from its intended position. - Heavy bleeding: unexpected profuse bleeding that may need intervention.

Before using Levosert One, clinicians should assess patient history and ensure appropriate conditions are met. - Pregnancy contraindication: do not insert in a known or suspected pregnancy. - Uterine abnormalities: avoid placement in women with fibroids, congenital anomalies, or significant scarring. - Active pelvic infection: postpone insertion until infection resolves. - Unexplained vaginal bleeding: investigate before device placement. - Follow‑up checks: schedule routine examinations to confirm correct IUS position. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Levosert One may interact with medications that affect levonorgestrel metabolism or hormone balance.

Major Interactions (Avoid): - Rifampin, carbamazepine, phenytoin, or St. John's wort: strong enzyme inducers that can markedly reduce levonorgestrel levels. - Antifungal agents such as ketoconazole: may increase systemic exposure.

Moderate Interactions (Monitor Closely): - Antiretroviral drugs (e.g., efavirenz): may modestly lower hormone concentrations. - Certain antibiotics (e.g., griseofulvin): limited effect but monitoring is advised. - Hormonal therapies (e.g., estrogen‑containing products): may alter bleeding patterns and require clinical observation.